FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Comment-MedSci.cn

FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Comment

Jafar, TH

Jafar, TH (corresponding author), Duke NUS Med Sch, Programme Hlth Serv & Syst Res, Singapore 169857, Singapore.; Jafar, TH (corresponding author), Singapore Gen Hosp, Dept Renal Med, Singapore, Singapore.; Jafar, TH (corresponding author), Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA.